Skip to content
DataLookout
Menu

NCT06390865

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 6 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027
  2. Notable Eligibility criteria expanded, about 27 words
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description revised
  3. Notable Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v8
  4. Minor Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)…v5
  5. Notable Primary and study completion dates: Jan 6, 2025 to Dec 31, 2025v3
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective response rate (ORR)
Timeframe: Up to 3 years

Secondary (3)

Overall survival (OS)
6-month progression free survival (PFS)
Progression free survival

Arms and interventions

Treatment (sapanisertib [MLN0128 (TAK-228)])Experimental

Patients receive sapanisertib (MLN0128 \[TAK-228\]) PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients also undergo biopsies and blood sample collection on study.

Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging

Drugs: Sapanisertib

Sites

1 site in 1 country

  • ECOG-ACRIN Cancer Research GroupPhiladelphia, Pennsylvania, United States